Litigation Details for Anacor Pharmaceuticals, LLC v. Dr. Reddys Laboratories, Ltd. (D. Del. 2021)

Anacor Pharmaceuticals, LLC v. Dr. Reddys Laboratories, Ltd. (D. Del. 2021)

Docket		Date Filed	2021-09-24
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Jennifer L. Hall
Patents	8,039,451; 8,168,614; 8,501,712; 9,682,092
Link to Docket	External link to docket

Details for Anacor Pharmaceuticals, LLC v. Dr. Reddys Laboratories, Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-09-24	1	Complaint	U.S. Patent No. 8,039,451 (“the ’451 patent”), U.S. Patent No. 8,168,614 (“the ’614 patent”), U.S….S. Patent No. 8,501,712 (“the ’712 patent”), and U.S. Patent No. 9,682,092 (“the ’092 patent”). The… The ’451 patent, the ’614 patent, the ’712 patent, and the ’092 patent are referred to collectively… This is a civil action for patent infringement under the patent laws of the United States, Title… THE PATENTS-IN-SUIT 6. On October 18, 2011, the United States Patent and Trademark	External link to document
2021-09-24	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,039,451 B2 ;8,168,614 B2 ;8,501,712…24 September 2021 1:21-cv-01348 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Anacor Pharmaceuticals, LLC v. Dr. Reddy's Laboratories, Ltd., 1:21-cv-01348

Last updated: March 11, 2026

Case Overview

Anacor Pharmaceuticals filed suit against Dr. Reddy's Laboratories in the U.S. District Court for the District of Delaware, asserting patent infringement related to its topical medication, crisaborole (marketed as Eucrisa). The case number is 1:21-cv-01348. The proceedings focus on allegations that Dr. Reddy’s Laboratories infringed U.S. Patent Nos. 9,049,618 and 9,166,238, which cover formulations and methods associated with crisaborole.

Litigation Timeline

• Filing Date: August 5, 2021
• Initial Complaint: Alleged infringement of patents related to crystallization and formulation methods.
• Defendant Response: Dr. Reddy's filed a motion to dismiss or otherwise challenge the validity of the patents in December 2021.
• Additional Pleadings: Both sides submitted briefs on patent validity, infringement scope, and potential jurisdiction issues through early 2022.
• Summary Judgment/Trial: As of the latest update (mid-2023), the case remains in pre-trial status pending potential settlement or further motions.

Patent Claims

The patents involve claims covering:

• Crystallization methods: Processes to produce stable crystalline forms of crisaborole.
• Formulation compositions: Specific excipient combinations improving drug stability and delivery.
• Method of use: Procedures for topical application with optimized bioavailability.

Infringement and Defense

Anacor alleges Dr. Reddy’s Laboratories produces generic formulations that infringe on the claims, especially concerning crystalline forms and excipient compositions. Dr. Reddy's defends the patents' validity, arguing the claims are either anticipated or obvious based on prior art. Furthermore, the defendant questions the scope of the patents and whether their generic products fall within the asserted claims.

Patent Validity Challenges

• Prior Art: Defendants cite earlier crystallization techniques and formulation patents to challenge novelty.
• Obviousness: Arguments suggest the claims are obvious combinations of known methods and compounds.
• Patent Term: The patents are approximately 8-10 years from expiration, with potential implications for validity defense strategies.

Court Proceedings and Implications

The case’s procedural posture involves patent validity arguments and potential injunction considerations. If Dr. Reddy’s delivers an invalidity ruling, it could open pathways for generic market entry, impacting Anacor’s market share and revenue from crisaborole. Conversely, a finding for Anacor upholds the patent protections, delaying generic entry.

Market and Commercial Impact

Given the topical market, particularly for eczema treatment, an adverse ruling could allow Dr. Reddy’s to launch generic crisaborole, intensifying competition and pressuring Anacor’s pricing and market share. The case exemplifies the broader patent litigation environment in the dermatology drug sector, which features frequent patent disputes over formulation and manufacturing patents.

Appendices: Documented Motions and Court Filings

Date	Document Type	Summary
Dec 2021	Motion to Dismiss	Dr. Reddy's challenges patent validity, citing prior art.
Mar 2022	Response to Motion	Anacor counters that the patents are novel and non-obvious.
Aug 2022	Summary Judgment Motions	Parties submit substantive arguments on validity and infringement.

Potential Outcomes

• Patents upheld: Delays or prevents generic entry for several years post-trial.
• Patents invalidated: Opens market to generics, significantly reducing Anacor’s revenue.
• Settlement agreement: Possible licensing or patent license arrangements to avoid protracted litigation.

Key Takeaways

This case underscores the importance of patent strategy in pharmaceutical R&D, particularly the scrutiny around crystallization and formulation patents. The outcome will influence competitive dynamics in topical medications, with broader regulatory and market implications.

FAQs

1. What patents are involved in the Anacor v. Reddy's case?
   U.S. Patent Nos. 9,049,618 and 9,166,238, covering formulations and crystallization methods for crisaborole.

2. What is the primary legal issue?
   Whether Dr. Reddy’s infringing products violate the asserted patents and whether those patents are valid.

3. How could an adverse ruling affect the market?
   It can enable generic manufacturers to launch competing crisaborole formulations, reducing Anacor’s market share and profits.

4. What defenses does Dr. Reddy’s utilize?
   Challenges based on prior art, obviousness, and patent validity arguments.

5. What is the current status?
   As of mid-2023, the case remains in pre-trial phase with unresolved motions and potential settlement discussions.

References

1. U.S. District Court for the District of Delaware. (2021). Case No. 1:21-cv-01348. Litigation documents.
2. Patent filings and public records from USPTO.
3. Market reports on topical dermatological drugs.